Patient P-02401
Therapy response
Improving
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
78%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 70 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 71 GI-04 recommended — GI Support Protocol GI-04
- Day 72 Patient accepted — Started GI-04 in the companion
- Day 80 GI symptom burden −28% vs expected — GI Support Protocol GI-04
- Day 86 Tolerance state changed — Unstable → Improving
- Day 93 ME-01 recommended — Monitoring Escalation ME-01
- Day 94 Patient accepted — Started ME-01 in the companion
- Day 97 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 70.
Primary contributors, last 14 days
- GI instability+5
- Toxicity+4
What helped?
- GI Support Protocol GI-04Day 71Result: symptom burden −28%
- Monitoring Escalation ME-01Day 93Result: deterioration detected before clinical escalation
LIFE OS recommendation
Supportive Compound SC-12
67%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 69% showed improvement
- median effect visible after 6 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 63 and rising
- WearableSleep 6.0 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 33/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↓70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 55
- Autonomic recovery ↓65
- WearableResting HR 72 bpm
- Wearable2,960 steps/day
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 47
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Intermediate metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
Microbiome
Shannon diversity 3.1 · butyrate capacity 33/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 46 ms
- Sleep
- 6.2 h
- Steps
- 2,813
- Resting HR
- 69 bpm
Daily log: GI score 63, nutritional resilience 40, adherence 51.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02483 | 23% | S06 | BR-03 | no change | 64 |
| P-02087 | 21% | S01 | BR-03 | no change | 40 |
| P-02009 | 34% | S08 | CR-01 | improved | 64 |
| P-02025 | 34% | S15 | CR-01 | improved | 61 |
| P-02054 | 34% | S01 | CR-01 | improved | 57 |
| P-02151 | 34% | S04 | CR-01 | improved | 49 |
| P-02233 | 32% | S16 | CR-01 | improved | 66 |
| P-02154 | 31% | S16 | CR-01 | improved | 57 |
| P-02395 | 24% | S12 | DT-01 | improved | 57 |
| P-02339 | 22% | S03 | DT-01 | improved | 50 |
| P-02491 | 22% | S09 | DT-01 | no change | 65 |
| P-02641 | 22% | S05 | DT-01 | no change | 45 |